Abstract
Objective The association between maternal HBV infection and adverse pregnancy outcomes remains controversial and the prenatal screening features was not investigated though they strongly indicate adverse pregnancy outcomes. We conducted a retrospective cohort study to determine the association between maternal HBV infection and adverse pregnancy outcomes and the result of prenatal screening.
Design The information from 65,257 pregnant women who performed non-invasive prenatal screening (NIPS) in second-trimester from July 2015 to Nov 2019 in Suzhou, China were collected. The participants were divided into the group of “control” (n = 63,591) and “exposure” (n = 1,666). Meanwhile, eight types of adverse pregnancy outcomes in history and twelve prenatal screening results in the second-trimester of current pregnancy were investigated by estimating and adjusting their risk ratios (aRR) for women between HBV infected and uninfected using multivariate logic regression.
Result Our results suggested that women infected with HBV have higher risks on the biochemical pregnancy, extrauterine pregnancy and three kinds of screen result for fetal Down’s syndrome (DS) than women with HBV un-infected. Meanwhile, the diagnostic result for the positive result of fetal Down syndrome in NIPS suggested the 98% additional risk in women with HBV infected than uninfected and supported by all adjusted models.
Conclusion Taken together, maternal HBV infection is an independent risk factor of biochemical pregnancy, extrauterine pregnancy, and fetal Down’s syndrome. It also indicates the influence of maternal HBV infection way across all gestation.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work is supported by Jiangsu Provincial Commission of Health and Family Planning Research Project (X201604), Jiangsu Maternal and Children health care key discipline (FXK201748), Jiangsu Maternal and Children health care research project (F201603), Jiangsu Provincial Medical Innovation Team (CXTDB2017013), Suzhou Key Medical Center (SZZX201505), Suzhou Introduced Project of Clinical Medical Expert Team (SZYJTD201708)
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.
